文献速递泌尿男性生殖肿瘤

ctDNA指导的肌层浸润性膀胱癌根治术后免疫治疗:TOMBOLA试验结果

ctDNA-guided immunotherapy following radical cystectomy for muscle-invasive bladder cancer: results from the TOMBOLA trial.
PubMed 文献 · Ann Oncol · 2026-01-14

TOMBOLA是一项丹麦多中心单臂II期试验,评估术后系列ctDNA检测指导免疫治疗。192例肌层浸润性膀胱癌患者入组,178例可评估者中104例(58%)在根治术后2年内ctDNA阳性,ctDNA阳性者接受阿替利珠单抗,60%(50/84)达到完全缓解,ctDNA阴性者1年无复发生存率97%。

要点

  • 术后ctDNA检测可预测肌层浸润性膀胱癌复发风险并指导个体化术后管理。
  • ctDNA阳性低危患者可能从早期免疫治疗获益。
  • ctDNA阴性高危患者或可安全避免辅助治疗而不影响结局。

核心结论

  • 新辅助化疗及根治术后肿瘤知情ctDNA检测可预测复发风险并实现肌层浸润性膀胱癌个体化术后管理。
  • ctDNA阳性低危患者可能从早期免疫治疗获益,ctDNA阴性高危患者或可安全避免辅助治疗。

研究设计与样本

  • TOMBOLA为丹麦多中心、开放标签、单臂II期试验,评估系列ctDNA检测指导术后免疫治疗。
  • 入组cT2-4aN0-1M0肌层浸润性膀胱癌患者,接受新辅助化疗及根治术,术后以肿瘤知情ctDNA assay监测。
  • ctDNA阳性者无论影像如何启动阿替利珠单抗最长1年,ctDNA阴性者仅在影像学发现转移时接受免疫治疗。
  • 主要终点为分子及影像学完全缓解,关键次要终点包括无复发生存和总生存。

主要发现

  • 共入组192例,意向治疗人群178例可评估(中位随访34个月),104例(58%)在根治术后2年内ctDNA阳性,其中63%在4个月内阳性。
  • ctDNA检测至影像确认复发的中位领先时间为90天(范围-61至961天)。
  • ctDNA阳性患者中84例完成阿替利珠单抗并有可评估的扫描和ctDNA分析,60%(50/84)达到主要终点完全缓解。
  • 1年无复发生存率在ctDNA阴性患者为97%,在ctDNA阳性患者为76%。
  • 预设生物标志物分析显示ctDNA状态与水平、风险分层及免疫相关基因表达特征与复发风险和免疫治疗反应相关,治疗耐受良好无新安全性问题。

临床怎么用

  • 肌层浸润性膀胱癌根治术后可用肿瘤知情ctDNA检测进行复发风险分层。
  • ctDNA阳性患者可考虑早期启动阿替利珠单抗治疗而不必等待影像学复发。
  • ctDNA阴性高危患者可在不损害结局的前提下安全避免辅助免疫治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Standard treatment of localized muscle-invasive bladder cancer (MIBC) is neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC), but ∼50% of patients relapse within 2 years. Adjuvant immunotherapy is currently administered based on pathology and clinical assessment in high-risk patients only, potentially resulting in under- and overtreatment. PATIENTS AND METHODS: TOMBOLA is a Danish, multicenter, open-label, single-arm phase II trial evaluating serial circulating tumor DNA (ctDNA) testing to guide postoperative immunotherapy. Low- and high-risk patients with MIBC (cT2-4aN0-1M0) treated with NAC and RC were monitored postoperatively with tumor-informed ctDNA assays. ctDNA-positive patients initiated atezolizumab for up to 1 year, irrespective of imaging; ctDNA-negative patients received immunotherapy only upon radiographic detection of metastases. The primary endpoint was molecular and radiographic complete response. Key secondary endpoints included recurrence-free survival and overall survival. RESULTS: In total 192 patients were enrolled, and among 178 assessable patients in the intention-to-treat population (median follow-up 34 months), 104 (58%) were ctDNA-positive within 2 years after RC, 63% within 4 months. The median lead time from ctDNA detection to imaging-confirmed recurrence was 90 days (range -61 to 961 days). Of the ctDNA-positive patients, 84 completed atezolizumab and had scanning and ctDNA analyses available for primary endpoint assessment. Some 60% (50/84) of patients achieved the primary endpoint of complete response. One-year recurrence-free survival was 97% in ctDNA-negative patients and 76% in ctDNA-positive patients. Prespecified biomarker analyses showed that ctDNA status and levels, risk stratification, and immune-related gene expression signatures were associated with both recurrence risk and response to immunotherapy. Treatment was well tolerated with no new safety concerns. CONCLUSIONS: Tumor-informed ctDNA testing after NAC and RC predicts recurrence risk and enables personalized postoperative management in MIBC. TOMBOLA demonstrates that ctDNA-positive, low-risk patients may benefit from early immunotherapy, while ctDNA-negative high-risk patients may safely avoid adjuvant treatment without compromising outcomes.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Dyrskjøt L, Birkenkamp-Demtröder K, Nordentoft I, et al. ctDNA-guided immunotherapy following radical cystectomy for muscle-invasive bladder cancer: results from the TOMBOLA trial. Ann Oncol. 2026. PMID: 41544704. doi:10.1016/j.annonc.2025.12.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。